Kodiak Sciences Inc. has announced follow-up data from the APEX study evaluating KSI-101 in patients with macular edema secondary to inflammation (MESI). The results demonstrate that ≥90% of patients in the top two dose levels (5 mg and 10 mg) achieved and sustained absence of intraretinal and subretinal fluid through week 20. More than half of the patients experienced a gain of 15 or more letters in best corrected visual acuity (BCVA) by week 20. The top two dose levels have been advanced into the Phase 3 PEAK and PINNACLE studies, which are currently enrolling patients at a faster-than-expected pace. The complete study results, including week 24 data, are scheduled to be presented by Dr. Sumit Sharma at the Angiogenesis, Exudation, and Degeneration 2026 Annual Meeting on February 7, 2026.